Report from the CMDh meeting held on 21th, 22nd and 23rd May 2012 Impact of the implementation of the new pharmacovigilance legislation (Regulation (EU) No[removed]and Directive[removed]EU) on Marketing Authorisations - 22nd of May - Document - PDFSEARCH.IO

First Page	Meta Content
	Report from the CMDh meeting held on 21th, 22nd and 23rd May 2012 Impact of the implementation of the new pharmacovigilance legislation (Regulation (EU) No[removed]and Directive[removed]EU) on Marketing Authorisations Add to Reading List Document Date: 2012-06-11 11:55:08 Open Document File Size: 307,38 KB Share Result on Facebook City Copenhagen / / Country Denmark / / / Event Product Issues / Product Recall / / / IndustryTerm biological others applications / medicinal product / blood product applications / repeat use applications / hybrid applications / chemical substances / active substance applications / authorised reference product / generic applications / paracetamol solution / medicinal products / chemical substance / category products / pharmaceutical forms / / Organization European Union / European Medicines Agency / CMDh Secretariat / European Commission / / Person Peter Bachmann / / / Position chair / / Product CMDh / tamsulosin hydrochloride / / ProgrammingLanguage EC / / PublishedMedium the Best Practice Guide / the CMDh Best Practice Guide / / Technology http / jsp / / URL www.hma.eu/cmdh.html / http / SocialTag Clinical research European Medicines Agency Health Drug safety Pharmacovigilance Treaties of the European Union European Union Pharmaceutical sciences Pharmacology Pharmaceutical industry

Report from the CMDh meeting held on 21th, 22nd and 23rd May 2012 Impact of the implementation of the new pharmacovigilance legislation (Regulation (EU) No[removed]and Directive[removed]EU) on Marketing Authorisations Add to Reading List